Boehringer Ingelheim and Peking University (PKU) in China have formed a strategic partnership with the aim of jointly advancing early science innovation across a range of areas of high medical need.

The partnership will implement a multi-faceted collaboration model that will consist of project-based research, a joint post-doctorate fellowship program, and a number of Boehringer Ingelheim-endowed investigators. The partnership aims to strengthen Boehringer Ingelheim’s portfolio of early and unique pipeline projects.

PKU is a national comprehensive university with disciplines in the natural sciences, humanities, social sciences, technological sciences, information science and engineering, and medical sciences. Currently, there are more than 20,000 faculty and staff members, more than 40,000 undergraduate and graduate students, and more than 347 institutes and research centers at the university. Some of its strong disciplines relevant to drug discovery include life sciences, chemistry, medical and pharmaceutical sciences as well as 10 affiliated hospitals.

Source: Boehringer Ingelheim